The challenge procedure influences the extent of allergen-induced urinary excretion of leukotriene E4
- 1 April 2000
- journal article
- research article
- Published by Wiley in Clinical and Experimental Allergy
- Vol. 30 (4) , 585-589
- https://doi.org/10.1046/j.1365-2222.2000.00738.x
Abstract
Background Cysteinyl‐leukotrienes are central mediators in asthma and urinary leukotriene E4 (LTE4) is a reliable marker of their endogenous formation. Objective This study tested the hypothesis that the procedure used for allergen bronchoprovocation influences the bronchoconstrictor response and the amount of LTE4 excreted following allergen challenge. Methods Seven atopic asthmatic men underwent two allergen bronchoprovocations 4 weeks apart. The same total dose of allergen was given at both sessions, cumulatively on one occasion and as a single dose at the other session. Urine was collected in hourly samples before and after challenge and LTE4 was measured with previously validated methodology. Results The mean (± se) drop in FEV1 was not significantly different between the cumulative (29 ± 2.4%) and the single dose challenge (25 ± 2.8%). There was a significant increase in post‐challenge levels of urinary LTE4 after both sessions. The peak excretion of LTE4 occurred 1 h following the maximal drop in FEV1 for both challenges. However, the post‐challenge increase in urinary LTE4 was significantly larger at the cumulative session. In fact, the net increase (post‐challenge minus prechallenge) of urinary LTE4 was more than twofold higher after the cumulative session (AUC 0–3 h post‐challenge: 46.7 ± 8.2 vs 22.1 ± 9.8, P < 0.05). Conclusion The peak excretion of urinary LTE4 occurred within 2 h after the termination of either challenge but the magnitude of urinary excretion of LTE4 was larger when cumulative challenge was performed. The findings are important to consider when designing studies where allergen‐induced urinary excretion of LTE4 is an outcome variable.Keywords
This publication has 19 references indexed in Scilit:
- Urinary excretion of inflammatory mediators during allergen‐induced early and late phase asthmatic reactionsClinical and Experimental Allergy, 1998
- Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAYx 1005Thorax, 1997
- Validation and application of a new simple strategy for measurements of urinary leukotriene E4 in humansClinical and Experimental Allergy, 1995
- The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivoJournal of Allergy and Clinical Immunology, 1995
- The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmaticsEuropean Respiratory Journal, 1994
- Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients.Thorax, 1991
- Urinary leukotriene E4 levels during early and late asthmatic responses†Journal of Allergy and Clinical Immunology, 1990
- Leukotriene C elimination and metabolism in manJournal of Allergy and Clinical Immunology, 1990
- URINARY LEUKOTRIENE E4 AFTER ANTIGEN CHALLENGE AND IN ACUTE ASTHMA AND ALLERGIC RHINITISThe Lancet, 1989
- The excretion of leukotriene E4 into urine following inhalation of leukotriene D4 by human individualsBiochemical and Biophysical Research Communications, 1987